The clinical study will evaluate the sensitivity and specificity of X-ray mammography (XRM) and automated breast ultrasound system (ABUS) together, as compared to XRM alone, as a breast cancer screening method in women with greater than 50% parenchymal density.
Bob Foley, U-System’s vice president of clinical affairs, said: “We are initiating this multi-center study with our somov to address that population of women with dense breasts. This is an undertaking that U-Systems feels is vital in the battle to find cancers earlier and at a more curable stage.
“We believe that the somoInSIGHT study will demonstrate that screening dense breasted patients with ABUS and XRM is more beneficial than XRM alone.”